ADALIMUMAB

Brand name:

• Abrilada®

Pharmaceutical company:

Pfizer Australia Pty Ltd

Condition/indication:
(therapeutic use)

• Severe Crohn disease; Moderate to severe ulcerative colitis; Severe active juvenile idiopathic arthritis; Complex refractory fistulising Crohn disease; Severe active rheumatoid arthritis; Severe psoriatic arthritis; Ankylosing spondylitis; Severe chronic plaque psoriasis; Moderate to severe hidradenitis suppurativa.

PBAC Submission type:

Change to listing (Category 3-4)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – July 2021

Related medicines:

--

Submission received for:

July 2021 PBAC meeting

Opportunity for consumer comment:

Open 21/03/2021 and close 26/05/2021 (see PBS Website)

PBAC meeting:

Held on 07/07/2021

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

07/02/2024

Lodgement of required documentation:

23/02/2024

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 13/05/2024

Status:

Finalised

Government processes:

Commenced on 20/05/2024

Medicine listed on the PBS:

01/08/2024 (see PBS schedule)

---